Generate a tailored SOP for Dr. Phillip Scott. Improve your application with a focused, well-structured draft.
Dr. Phillip Scott's current research focuses on understanding the development, regulation, and maintenance of CD4+ and CD8+ T cells and the design of new vaccines and immunotherapies for infectious diseases. His laboratory primarily works with experimental murine infections of the protozoan parasite, Leishmania, providing a well-characterized model for T helper cell differentiation. They use IL-12 adjuvants to promote Th1 cell development and have shown that combined drug and IL-12 therapy can promote a Th2 to Th1 switch. The implications of these findings are significant for the control and treatment of infectious diseases as well as autoimmunity and allergy. The research also highlights the limitations in understanding the maintenance of Th1 responses and the development of vaccines for human leishmaniasis. Dr. Scott's laboratory investigates the role of cytokines, antigen dose, CD8+ T cells, and regulatory T cells in the development of immunologic memory. Key aspects of their research include examining how different species of Leishmania interact with the host immune system and developing new treatments for chronic leishmaniasis. Current studies include collaborations in Brazil to understand the pathogenesis of L. braziliensis in patients, an organism that causes disfiguring chronic disease despite a strong immune response against it.
Wharton Doctoral programs cover fields like Finance, Marketing, Management, and Operations, Information and Decisions.